In-hospital resource utilization, worsening heart failure, and factors associated with length of hospital stay in patients with hospitalized heart failure: A Japanese database cohort study.

Autor: Mitani H; Medical Division, Novartis Pharma K.K., Tokyo, Japan. Electronic address: hironobu.mitani@novartis.com., Funakubo M; Medical Division, Novartis Pharma K.K., Tokyo, Japan., Sato N; Department of Cardiovascular Medicine, Kawaguchi Cardiovascular and Respiratory Hospital, Saitama, Japan., Murayama H; Medical Division, Novartis Pharma K.K., Tokyo, Japan., Rached RA; Medical Division, Novartis Pharma K.K., Tokyo, Japan., Matsui N; Real World Insights, IQVIA Solutions Japan K.K., Tokyo, Japan., Yoshida S; Statistical Services, IQVIA Solutions Japan K.K., Tokyo, Japan., Ishii T; Real World Insights, IQVIA Solutions Japan K.K., Tokyo, Japan., Oyama N; Medical Division, Novartis Pharma K.K., Tokyo, Japan.
Jazyk: angličtina
Zdroj: Journal of cardiology [J Cardiol] 2020 Oct; Vol. 76 (4), pp. 342-349. Date of Electronic Publication: 2020 Jul 04.
DOI: 10.1016/j.jjcc.2020.05.010
Abstrakt: Background: Our objective was to characterize cases of hospitalized heart failure (HHF) focusing on in-hospital resource utilization (particularly furosemide doses) and worsening heart failure (WHF), and identify which factors are associated with the length of stay (LOS).
Methods: Cases of HHF (≥20 years), excluding those undergoing surgical procedures and in-hospital deaths, were retrieved from the Japanese Diagnosis Procedure Combination database (April 2012 to March 2016). WHF was defined using eight components, including up-titration of intravenous drugs and non-pharmacological management.
Results: The mean age of 78,953 cases of HHF was 79 years and 51% were male. The median LOS was 17 days. The maximum daily dose and cumulative dose of furosemide (mean ± standard deviation) were 43.3 ± 56.0 mg and 215.6 ± 450.6 mg, respectively, for intravenous furosemide, and 44.0 ± 37.3 mg and 523.3 ± 675.4 mg, respectively, for oral furosemide. The incidence of WHF was 36.1% during hospitalization and 19.3% from 6th hospital day to discharge. The mean number of WHF components was 1.4 ± 0.7 during hospitalization and 1.3 ± 0.6 from 6th hospital day. Regression analyses showed that the number of WHF components from 6th hospital day, pneumonia, and hyponatremia were strongly associated with longer LOS.
Conclusions: These findings in patients with HHF could be vital to focus future efforts to improve the therapeutic strategies for heart failure.
(Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: